Catalog No.
DVV02811
Expression system
Mammalian Cells
Species reactivity
Human respiratory syncytial virus A (strain A2)
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
Concentration
2.9 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P03420
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ADI-14359
Clone ID
ADI-14359
Note
For research use only. Not suitable for clinical or therapeutic use.
A Statistical Model to Predict Protection Against Infant Respiratory Syncytial Virus Disease Through Maternal Immunization., PMID:39772012
Evaluating the Impact of N-Glycan Sequon Removal in the p27 Peptide on RSV F Protein Immunogenicity and Functionality., PMID:39772158
Fumarprotocetraric acid and geraniin were identified as novel inhibitors of human respiratory syncytial virus infection in vitro., PMID:39776441
Evaluation of an F Protein-Based Recombinant Protein for Immunization Against Respiratory Syncytial Virus., PMID:39791530
The recent landscape of RSV vaccine research., PMID:39802673
Protective or limited? Maternal antibodies and RSV-associated lower respiratory tract infection in hospitalized infants aged 28-90 days., PMID:39845974
Anti-Idiotypic Antibody as a Booster Vaccine Against Respiratory Syncytial Virus., PMID:39852814
An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease., PMID:39852831
Robust and Long-Lasting Immunity and Protection in Mice Induced by Lipopolyplex-Delivered mRNA Vaccines Expressing the Prefusion Protein of Respiratory Syncytial Virus., PMID:39852872
Efficacy, immunogenicity, and safety of an investigational maternal respiratory syncytial virus prefusion F protein-based vaccine., PMID:39879629
Molecular characterization of RSV infections in elderly patients during the 2023/2024 season in the era of nirsevimab introduction., PMID:39895281
A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus., PMID:39910047
Enhanced construction of a bivalent adenovirus-based vaccine for preventing childhood pathogens: Human respiratory syncytial virus and norovirus., PMID:39952326
Epitope-focused vaccine immunogens design using tailored horseshoe-shaped scaffold., PMID:39966941
Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates., PMID:39969879
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial., PMID:39974075
Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines., PMID:40006644
Binding and neutralising antibodies to respiratory syncytial virus and influenza A virus in serum and bronchoalveolar lavage fluid of healthy adults in the United States: A cross-sectional study., PMID:40037127
Recovery of Antibody Immunity After a Resurgence of Respiratory Syncytial Virus Infections., PMID:40099894
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial., PMID:40120616
Layer-by-Layer Microparticle Vaccines Containing a S177Q Point Mutation in the Central Conserved Domain of the RSV G Protein Improves Immunogenicity., PMID:40126409
Generation of nanobodies against the F protein of respiratory syncytial virus and establishment of an indirect immunofluorescence assay., PMID:40130866
Intranasal Inoculation of Cationic Crosslinked Carbon Dots-Adjuvanted Respiratory Syncytial Virus F Subunit Vaccine Elicits Mucosal and Systemic Humoral and Cellular Immunity., PMID:40135196
RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera., PMID:40161760
Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4+ T cell response in all vaccinees., PMID:40169094
Strength and durability of RSV pre-fusion F IgG following infection and exposure in a household cohort, 2014-2022., PMID:40176487
Evaluation of dual pathogen recognition receptor agonists as adjuvants for respiratory syncytial virus - virus-like particles for pulmonary delivery., PMID:40176816
A bivalent mRNA vaccine against RSV infection in rodent models., PMID:40196112
Recent advances in the prevention and treatment of respiratory syncytial virus disease., PMID:40202895
Development and evaluation of ELISA serological immunoassays for influenza and respiratory syncytial viruses., PMID:40215609
Functional implications of respiratory syncytial virus F sequence variability: a comparative analysis using contemporary RSV isolates., PMID:40227055
Summary of the National Advisory Committee on Immunization (NACI) Statement on the Prevention of Respiratory Syncytial Virus (RSV) in Infants., PMID:40241712
Immunogenicity, safety, and tolerability of a β-glucan-CpG-adjuvanted respiratory syncytial virus vaccine in Japanese healthy participants aged 60 to 80 years: A phase 2, randomized, double-blind, dose-finding study., PMID:40257186
Progress on Respiratory Syncytial Virus Vaccine Development and Evaluation Methods., PMID:40266209
A single amino acid mutation alters multiple neutralization epitopes in the respiratory syncytial virus fusion glycoprotein., PMID:40295799
Nirsevimab and Maternal Respiratory Syncytial Virus Vaccine Recommendations for the Pediatric Population., PMID:40305635
Editorial: Surveillance of Seasonal Respiratory Syncytial Virus (RSV) Infection in Children and Vulnerable Adults Drives Vaccine Development and New Immunization Programs., PMID:40308086
Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants., PMID:40317387
Immunogenicity evaluation of respiratory syncytial virus prefusogenic-F based virus-like-particles consisting of G and M proteins in mice., PMID:40334534
Synthetic Bacterial Membrane Vesicles as Versatile Antigen-Display Platforms against Respiratory Syncytial Virus., PMID:40343468
Clinical Insights and Advancements in Human Metapneumovirus Management and Prognosis., PMID:40351504
Respiratory syncytial virus: health burden, disease prevention, and treatment-recent progress and lessons learned., PMID:40420998
Immunogenicity of RSV Fusion Protein Adsorbed to Non-Pathogenic Bacillus subtilis Spores: Implications for Mucosal Vaccine Delivery in Nonclinical Animal Models., PMID:40426939
Single-Dose Intranasal Immunization with ChAd68-Vectored Prefusion F Vaccines Confers Sustained Protection Against Respiratory Syncytial Virus in Murine Models., PMID:40432136
Hydrophobic residue substitutions enhance the stability and in vivo immunogenicity of respiratory syncytial virus fusion protein., PMID:40434102
The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama., PMID:40458968
Fc-effector functional antibody assays for SARS-CoV-2 variants of concern., PMID:40463385
Plasmonic optical fiber biosensors for ultra-low detection of respiratory syncytial virus via point-of-care tests., PMID:40467662
Respiratory syncytial virus prophylaxis for children in Africa: Challenges, opportunities and public health strategies., PMID:40469396
Intention to Use RSVpreF Vaccine or Nirsevimab to Prevent Infant RSV Among Pregnant Individuals., PMID:40472256
For research use only. Not for human or drug use.
